C7R-GD2.CART cells

also known as C7R-GD2.CARTs

Developed for: neuroblastoma · osteosarcoma · breast phyllodes tumor · diffuse intrinsic pontine glioma · embryonal neoplasm · ependymal tumor · Ewing sarcoma · rhabdomyosarcoma
+1 more
· uveal melanoma
Investigated by: Baylor College of Medicine · Center for Cell and Gene Therapy, Baylor College of Medicine · Cancer Prevention Research Institute of Texas · ChadTough Defeat DIPG Foundation · DIPG DMG Research Funding Alliance · The Faris Foundation
+2 more
· The Methodist Hospital Research Institute · Violet Foundation for Pediatric Brain Cancer

2020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT07211737	Aug 2026 → Apr 2029 expected	neuroblastoma, osteosarcoma	Baylor College of Medicine	Not yet recruiting	No outcome recorded
Phase 1	NCT04099797	Feb 2020 → Feb 2027 expected	diffuse intrinsic pontine glioma, embryonal neoplasm, ependymal tumor	Baylor College of Medicine	Recruiting	No outcome recorded
Phase 1	NCT03635632	Apr 2019 → May 2023 overdue	Ewing sarcoma, breast phyllodes tumor, neuroblastoma, osteosarcoma +2	Baylor College of Medicine	Active not recruiting	No outcome recorded

Every value below carries the sentence it was read from. 4 sources stand behind the page.

Field	Value	Cited text
Known as	C7R.GD2.CAR-T cells	“The C7R.GD2.CAR-T cells and i15.NKG2D.zeta-NK cells are investigational products not approved by the Food and Drug Administration.” NCT07211737 ↗ 2 NCT03635632 ↗ NCT04099797 ↗
Known as	C7R-GD2.CARTs	“To enhance T cell activity against GD2+ CNS malignancies, we modified GD2-directed CART cells (GD2.CARTs) with a constitutively active interleukin (IL)-7 receptor (C7R-GD2.CARTs).” PMID 38771986 ↗ May 2024
Action	Deplete	“that can recognize and kill brain cancer cells GD2.CAR” NCT04099797 ↗
Modality	Cell therapy	“special immune cells called T cells” NCT03635632 ↗
Route	Intravenous	“injection of GD2-C7R T cells into the vein through an IV line” NCT03635632 ↗